India's Rubicon Research rises as Motial Oswal begins coverage with 'buy'

Rubicon Research

31/10/2025 04:32

** Shares of pharmaceutical formulations co Rubicon Research RUBI.NS rise 2.3% to 623 rupees

** Motilal Oswal initiates coverage with "buy" rating, PT of 740 rupees; first brokerage to cover stock - per data compiled by LSEG

** Brokerage estimates annualised growth of 29%, 32%, and 43% in rev, EBITDA, and PAT, respectively
** Says growth driven by new generic launches, stronger focus on prescription-led business in CNS therapy, stable

R&D productivity, tighter supply chain management

** Adds, Rubicon's consistent compliance track record provides a strong backbone for growth in earnings and

return ratios

   ** Since its listing earlier this month, RUBI down nearly 3%

 (Reporting by Yagnoseni Das in Bengaluru)

 ((Yagnoseni.Das@thomsonreuters.com;))